1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Galectin Therapeutics, Inc. - Product Pipeline Review - 2015

Galectin Therapeutics, Inc. - Product Pipeline Review - 2015

  • August 2015
  • -
  • Global Markets Direct
  • -
  • 43 pages

Galectin Therapeutics, Inc. - Product Pipeline Review - 2015

Summary

Global Markets Direct’s, ‘Galectin Therapeutics, Inc. - Product Pipeline Review - 2015’, provides an overview of the Galectin Therapeutics, Inc.’s pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Galectin Therapeutics, Inc.’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Galectin Therapeutics, Inc. including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Galectin Therapeutics, Inc.’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Galectin Therapeutics, Inc.’s pipeline products

Reasons to buy

- Evaluate Galectin Therapeutics, Inc.’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Galectin Therapeutics, Inc. in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Galectin Therapeutics, Inc.’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Galectin Therapeutics, Inc. and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Galectin Therapeutics, Inc.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Galectin Therapeutics, Inc. and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues

Table Of Contents

Galectin Therapeutics, Inc. - Product Pipeline Review - 2015
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Galectin Therapeutics, Inc. Snapshot 5
Galectin Therapeutics, Inc. Overview 5
Key Information 5
Key Facts 5
Galectin Therapeutics, Inc. - Research and Development Overview 6
Key Therapeutic Areas 6
Galectin Therapeutics, Inc. - Pipeline Review 9
Pipeline Products by Stage of Development 9
Pipeline Products - Monotherapy 10
Galectin Therapeutics, Inc. - Pipeline Products Glance 11
Galectin Therapeutics, Inc. - Clinical Stage Pipeline Products 11
Phase II Products/Combination Treatment Modalities 11
Phase I Products/Combination Treatment Modalities 12
Galectin Therapeutics, Inc. - Early Stage Pipeline Products 13
Preclinical Products/Combination Treatment Modalities 13
Discovery Products/Combination Treatment Modalities 14
Galectin Therapeutics, Inc. - Drug Profiles 15
GR-MD-02 15
Product Description 15
Mechanism of Action 15
RandD Progress 15
GM-CT-01 18
Product Description 18
Mechanism of Action 18
RandD Progress 18
GM-CT-02 21
Product Description 21
Mechanism of Action 21
RandD Progress 21
GR-MD-01 22
Product Description 22
Mechanism of Action 22
RandD Progress 22
GM-CT-04 23
Product Description 23
Mechanism of Action 23
RandD Progress 23
GR-MD-03 24
Product Description 24
Mechanism of Action 24
RandD Progress 24
GR-MD-04 25
Product Description 25
Mechanism of Action 25
RandD Progress 25
Galectin Therapeutics, Inc. - Pipeline Analysis 26
Galectin Therapeutics, Inc. - Pipeline Products by Target 26
Galectin Therapeutics, Inc. - Pipeline Products by Route of Administration 27
Galectin Therapeutics, Inc. - Pipeline Products by Molecule Type 28
Galectin Therapeutics, Inc. - Pipeline Products by Mechanism of Action 29
Galectin Therapeutics, Inc. - Recent Pipeline Updates 30
Galectin Therapeutics, Inc. - Dormant Projects 39
Galectin Therapeutics, Inc. - Discontinued Pipeline Products 40
Discontinued Pipeline Product Profiles 40
GM-CT-01 40
Galectin Therapeutics, Inc. - Locations And Subsidiaries 41
Head Office 41
Appendix 42
Methodology 42
Coverage 42
Secondary Research 42
Primary Research 42
Expert Panel Validation 42
Contact Us 42
Disclaimer 43

List of Tables
Galectin Therapeutics, Inc., Key Information 5
Galectin Therapeutics, Inc., Key Facts 5
Galectin Therapeutics, Inc. - Pipeline by Indication, 2015 7
Galectin Therapeutics, Inc. - Pipeline by Stage of Development, 2015 9
Galectin Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015 10
Galectin Therapeutics, Inc. - Phase II, 2015 11
Galectin Therapeutics, Inc. - Phase I, 2015 12
Galectin Therapeutics, Inc. - Preclinical, 2015 13
Galectin Therapeutics, Inc. - Discovery, 2015 14
Galectin Therapeutics, Inc. - Pipeline by Target, 2015 26
Galectin Therapeutics, Inc. - Pipeline by Route of Administration, 2015 27
Galectin Therapeutics, Inc. - Pipeline by Molecule Type, 2015 28
Galectin Therapeutics, Inc. - Pipeline Products by Mechanism of Action, 2015 29
Galectin Therapeutics, Inc. - Recent Pipeline Updates, 2015 30
Galectin Therapeutics, Inc. - Dormant Developmental Projects,2015 39
Galectin Therapeutics, Inc. - Discontinued Pipeline Products, 2015 40

List of Figures
Galectin Therapeutics, Inc. - Pipeline by Top 10 Indication, 2015 7
Galectin Therapeutics, Inc. - Pipeline by Stage of Development, 2015 9
Galectin Therapeutics, Inc. - Monotherapy Products in Pipeline, 2015 10
Galectin Therapeutics, Inc. - Pipeline by Top 10 Target, 2015 26
Galectin Therapeutics, Inc. - Pipeline by Top 10 Route of Administration, 2015 27
Galectin Therapeutics, Inc. - Pipeline by Top 10 Molecule Type, 2015 28
Galectin Therapeutics, Inc. - Pipeline Products by Top 10 Mechanism of Action, 2015 29

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Tyrosine Protein Kinase Mer (Proto Oncogene c Mer or Receptor Tyrosine Kinase MerTK or MERTK or EC 2.7.10.1) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Tyrosine Protein Kinase Me ...

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘P27 (Negative Regulatory Factor or Nef) - Pipeline Review, H2 2016’, provides in depth analysis ...

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016

  • $ 3500
  • Company report
  • August 2016
  • by Global Markets Direct

Iduronate 2 Sulfatase (Alpha L Iduronate Sulfate Sulfatase or Idursulfase or IDS or EC 3.1.6.13) - Pipeline Review, H2 2016 Summary Global Markets Direct’s, ‘Iduronate 2 Sulfatase (Alpha L Iduronate ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.